Cadrenal Therapeutics, a biopharmaceutical company developing tecarfarin, a novel oral anticoagulant, has initiated discussions with Abbott about a potential pivotal study that would evaluate the efficacy and safety of tecarfarin in preventing blood clots in patients with recently implanted left ventricular assist devices (LVADs).
 
Tecarfarin, a late-stage Vitamin K Antagonist (VKA), is designed to offer a safer and more predictable anticoagulation profile compared to existing options. The drug has already secured Orphan Drug Designation from the FDA for its potential to prevent blood clots and strokes in LVAD patients.
 
Abbott’s HeartMate 3 LVAD is the current standard of care for patients with advanced heart failure. Recent data from the ARIES-HM3 study highlighted the importance of optimal anticoagulation management for improving outcomes with this device.
 
“We are pleased that Abbott has initiated a collaborative effort with us for this trial, which we believe is very important to LVAD patients,” said Quang Pham, Chairman and Chief Executive of Cadrenal Therapeutics. “We believe that tecarfarin has the potential to further improve AC treatment for HeartMate 3 patients.”
 
Cadrenal’s development program for tecarfarin has demonstrated promising results in previous clinical studies, particularly in patient populations with complex medical conditions often associated with LVAD implantation.